EGTX.ST STO
Egetis Therapeutics AB (publ)
1W: +16.5%
1M: +17.1%
3M: +55.6%
YTD: +77.6%
1Y: +74.5%
3Y: +121.7%
5Y: +70.6%
kr 9.18 ($0.91)
-0.26 (-2.75%)
Weekly Expected Move ±9.5%
kr 7
kr 8
kr 9
kr 10
kr 11
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$267M
-17.2% ▼
Capital Expenditures
$2M
+0.0% ▲
5Y CAGR: +128.7%
Free Cash Flow
-$269M
-17.9% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+100.0% ▲
Net Change in Cash
-$135M
-383.4% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$105M | -$194M | -$327M | -$344M | -$342M |
| Depreciation & Amort. | $2M | $3M | $4M | $0 | $0 |
| Stock-Based Comp. | $1M | $9M | $8M | $0 | $0 |
| Change in Working Capital | -$28M | $11M | $31M | $89M | $26M |
| Other Non-Cash Items | $154K | -$2M | $6M | $27M | $49M |
| Operating Cash Flow | -$130M | -$174M | -$278M | -$228M | -$267M |
| — Investing Activities — | |||||
| Capital Expenditures | -$172K | $0 | $0 | $0 | -$2M |
| Acquisitions (Net) | -$5M | -$2M | $0 | -$1M | -$1M |
| Investment Purchases | -$785K | $0 | $0 | $0 | $0 |
| Investment Sales | $6M | $0 | $0 | $0 | $0 |
| Other Investing | -$6M | $0 | -$100K | $0 | $0 |
| Investing Cash Flow | -$6M | -$2M | -$100K | -$1M | -$3M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$8M | -$9M | $106M | -$8M | -$29M |
| Stock Repurchased | $0 | $0 | $0 | -$2M | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$1M | $165M | -$29M | -$21M | -$3M |
| Financing Cash Flow | -$9M | $156M | $459M | $271M | $140M |
| Net Change in Cash | -$144M | -$16M | $176M | $48M | -$135M |
| Cash End of Period | $144M | $128M | $303M | $351M | $216M |
| Free Cash Flow | -$130M | -$174M | -$278M | -$228M | -$269M |